Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 49: 523-525, 2003; 10.1373/49.3.523
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (5)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Trapé, J.
Right arrow Articles by de Olaguer, J. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Trapé, J.
Right arrow Articles by de Olaguer, J. P.
Related Collections
Right arrow Cancer Diagnostics (since 2002)
(Clinical Chemistry. 2003;49:523-525.)
© 2003 American Association for Clinical Chemistry, Inc.

Letters to the Editor

Serum Concentrations of Vascular Endothelial Growth Factor in Advanced Non-Small Cell Lung Cancer

Jaume Trapé1a, Josep Buxó2 and Joaquim Pérez de Olaguer2

1 Laboratori Anàlisis Clíniques, and,
2 Secció Oncologia, Hospital General de Manresa, Althaia Xarxa Asistencial de Manresa, La Culla, s/n, 08240 Manresa (Barcelona), Spain

aAuthor for correspondence. Fax 34-93-8743859; e-mail hgmlaboratorio@aehh.org.

The first 20% of the full text of this article appears below.


To the Editor:

Vascular endothelial growth factor (VEGF) may play a role in tumor growth. Several biological activities of VEGF favor the growth of solid tumors, including mitogenic activity for vascular endothelial cells and inhibition of immature dendritic cells with a consequent decrease in immunity. VEGF is regulated by hypoxia, growth factors, interleukin-1 and -6, the oncogene ras, and the tumor suppressor gene p53 (1).

The role of VEGF in non-small cell lung cancer (NSCLC) patients treated with chemotherapy in still undetermined. We studied the serum concentrations of this cytokine in NSCLC patients with advanced disease and its correlation with carcinoembryonic antigen (CEA), CYFRA 21-1, CA125, and C-reactive protein (CRP).

We analyzed 33 healthy individuals, 23 patients with benign pulmonary disease (13 with . . . [Full Text of this Article]




The following articles in journals at HighWire Press have cited this article:


Home page
 NeurologyHome page
B. van de Langerijt, J. M. Gijtenbeek, H.P.M. de Reus, F. C.G.J. Sweep, A. Geurts-Moespot, J. C.M. Hendriks, A. C. Kappelle, and M. M. Verbeek
CSF levels of growth factors and plasminogen activators in leptomeningeal metastases.
Neurology, July 11, 2006; 67(1): 114 - 119.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
R. Zimmermann, J. Koenig, J. Zingsem, V. Weisbach, E. Strasser, J. Ringwald, and R. Eckstein
Effect of Specimen Anticoagulation on the Measurement of Circulating Platelet-Derived Growth Factors
Clin. Chem., December 1, 2005; 51(12): 2365 - 2368.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the American Association for Clinical Chemistry.